Elite Pharmaceuticals, Inc. (ELTP) reported a record fiscal year 2026, with total revenues increasing 77.1% to $148.9 million, compared to $84 million in the previous year. The company achieved operating income of $49.1 million, a 150.6% rise from $19.6 million a year earlier. Net income stood at $44.9 million, up from a net loss of $4.3 million in fiscal 2025, with basic earnings per share (EPS) at $0.04 versus a loss a year prior.
Despite these gains, ELTP’s stock has declined 13.7% since the earnings report, underperforming the S&P 500 Index, which gained 1.8%. Manufacturing fee revenues rose 80.3% to $147.8 million; however, licensing fees plummeted 48.5% to $1.1 million as the company transitions to in-house sales. Cash on hand increased to $29.8 million, while long-term debt fell to $4.7 million.
Management emphasized ongoing product launches and a robust pipeline as essential for future growth, though they did not provide formal guidance for fiscal 2027. Recent successes included the full-year contribution from Lisdexamfetamine and new introductions like generic Vyvanse and Methadone tablets.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
